BUSINESS SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Business Segment Information [Text Block]

BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Product revenues were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2015		2014		2015		2014
Virology
Baraclude (entecavir)	$	343	$	369	$	683	$	775
Hepatitis C Franchise(a)	479		—		743		—
Reyataz (atazanavir sulfate) Franchise	303		362		597		706
Sustiva (efavirenz) Franchise(b)	317		361		607		680
Oncology
Erbitux* (cetuximab)	169		186		334		355
Opdivo (nivolumab)	122		—		162		—
Sprycel (dasatinib)	405		368		780		710
Yervoy (ipilimumab)	296		321		621		592
Neuroscience
Abilify* (aripiprazole)(c)	107		555		661		1,095
Immunoscience
Orencia (abatacept)	461		402		861		765
Cardiovascular
Eliquis (apixaban)	437		171		792		277
Mature Products and All Other(d)	724		794		1,363		1,745
Total Revenues	$	4,163	$	3,889	$	8,204	$	7,700

*	Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information can be found at the end of this quarterly report on Form 10-Q.
(a)	Includes Daklinza (daclatasvir) and Sunvepra (asunaprevir) revenues of $382 million and $97 million for the three months ended June 30, 2015, respectively, and $562 million and $181 million for the six months ended June 30, 2015, respectively.
(b)	Includes alliance and other revenue of $276 million and $313 million for the three months ended June 30, 2015 and 2014, respectively, and $527 million and $585 million for the six months ended June 30, 2015 and 2014, respectively.
(c)	Includes alliance and other revenue of $70 million and $499 million for the three months ended June 30, 2015 and 2014, respectively, and $578 million and $940 million for the six months ended June 30, 2015 and 2014, respectively. BMS's U.S. rights to Abilify* expired on April 20, 2015.
(d)	Includes Diabetes Alliance revenues of $64 million and $27 million for the three months ended June 30, 2015 and 2014, respectively, and $118 million and $206 million for the six months ended June 30, 2015 and 2014, respectively. See "—Note 3. Alliances" for further information on the diabetes business divestiture.